Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen

Clinical Trial ID NCT00354263

PubWeight™ 1.57‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00354263

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity. Oncoimmunology 2014 0.81
2 Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci 2016 0.76
Next 100